Published in Diabetes Week, October 23rd, 2006
In a recent study presented at the International Conference on Alzheimer's Disease by investigators from the [U.S.] Veterans Affairs (VA) Puget Sound Health Care System in Seattle, Washington and the University of Washington School of Medicine, ViaNase intranasally delivered insulin or placebo to 24 study participants. Treatment was well-tolerated, with no serious adverse events or changes in plasma glucose or insulin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.